Trading in Calliditas Therapeutics AB's (Calliditas) started today, 29 June, on Nasdaq Stockholm. The Offering attracted very strong interest from institutional investors as well as the general public in Sweden and was substantially over-subscribed. The price per share was SEK 45, corresponding to a total value of the number of outstanding shares in Calliditas upon completion of the IPO of approximately SEK 1.5 billion.
Calliditas is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications, where the company can partially or completely participate in the commercialization.
Carnegie Investment Bank AB acted Sole Global Coordinator and Sole Bookrunner, Stifel Nicolaus Europe Limited acted Co-Bookrunner and Redeye AB acted Co-Lead Manager (together ”Managers”). Baker McKenzie acted legal advisors to the Managers as to Swedish and US law. The lawyers involved were mainly Joakim Falkner, Henric Roth and Johanna Flink from Baker McKenzie's Stockholm office and Adam Farlow and Roger James from its London office.